Bekoz, H. Et Al. 2020. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology , vol.99, no.11 , 2565-2576.

Bekoz, H., Ozbalak, M., Karadurmus, N., Paydas, S., Turker, A., Toptas, T., ... Tuglular, T. F.(2020). Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology , vol.99, no.11, 2565-2576.

Bekoz, Huseyin Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience," Annals of Hematology , vol.99, no.11, 2565-2576, 2020

Bekoz, Huseyin Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience." Annals of Hematology , vol.99, no.11, pp.2565-2576, 2020

Bekoz, H. Et Al. (2020) . "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience." Annals of Hematology , vol.99, no.11, pp.2565-2576.

@article{article, author={Huseyin Bekoz Et Al. }, title={Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience}, journal={Annals of Hematology}, year=2020, pages={2565-2576} }